TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37948170

Group type: EXPERIMENTAL
Intervention: PRISCA (patient-centered approach including healthy lifestyle promotion, pharmacological management of CVRFs, psychotropic drug optimization, and motivational follow-up)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: PRISCA
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 46
Study: 37948425

Group type: EXPERIMENTAL
Intervention: Ultrasound diagnostic tool
Number of subjects: 438

Group type: COMPARATOR
Intervention: Neurophysiological test (NPT)
Number of subjects: 438
Study: 37948612

Group type: EXPERIMENTAL
Intervention: Structured physical activity (PA) intervention
Number of subjects: 1377

Group type: COMPARATOR
Intervention: Healthy aging (HA) intervention
Number of subjects: 1377

Group type: EXPERIMENTAL
Intervention: Higher levels of physical activity (PA)
Number of subjects: 1377
Study: 37948704

Group type: EXPERIMENTAL
Intervention: Spiration Valve System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37948736

Group type: EXPERIMENTAL
Intervention: Inhaled Molgramostim
Number of subjects: 0
Study: 37948759

Group type: EXPERIMENTAL
Intervention: Neutralizing monoclonal antibodies (nmAbs)
Number of subjects: 2149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2149
Study: 37948791

Group type: EXPERIMENTAL
Intervention: Preoperative 6-minute walk distance (6MWD)
Number of subjects: 184
Study: 37948832

Group type: EXPERIMENTAL
Intervention: KW-6356 3 mg/day
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: KW-6356 6 mg/day
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 37949090

Group type: EXPERIMENTAL
Intervention: Moxidectin (8 mg)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Ivermectin (200 μg/kg bodyweight)
Number of subjects: 726
Study: 37949165

Group type: EXPERIMENTAL
Intervention: CDSS (ESR iGuide) with active decision support
Number of subjects: 32

Group type: COMPARATOR
Intervention: CDSS (ESR iGuide) without active decision support (control condition)
Number of subjects: 32
Study: 37949351

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 952

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg and 100 mg
Number of subjects: 952
Study: 37949432

Group type: EXPERIMENTAL
Intervention: 12-month pragmatic multidomain intervention
Number of subjects: 398
Study: 37949481

Group type: EXPERIMENTAL
Intervention: cSS+CMB+
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: CMB in cSS- patients
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: CMB in context of cSS+
Number of subjects: 673

Group type: COMPARATOR
Intervention: cSS-CMB-
Number of subjects: 673

Group type: COMPARATOR
Intervention: cSS-CMB+
Number of subjects: 673

Group type: COMPARATOR
Intervention: cSS+CMB-
Number of subjects: 673
Study: 37949595

Group type: EXPERIMENTAL
Intervention: Bicycle exercise
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Exergaming (Kinect Adventures)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Functional training
Number of subjects: 58
Study: 37949617

Group type: EXPERIMENTAL
Intervention: TIL treatment during chemotherapy without IFNa (n=13)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: TIL treatment with IFNa
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: TIL therapy
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: TIL infusions during platinum-based chemotherapy
Number of subjects: 16
Study: 37949619

Group type: EXPERIMENTAL
Intervention: Obstetrics and gynaecology (O&G) trainees
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Senior obstetrics and gynaecology (O&G) trainees
Number of subjects: 47
Study: 37949621

Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg oral daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37949622

Group type: EXPERIMENTAL
Intervention: Intrathrombus thrombolysis with a pierced balloon
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Upfront routine manual aspiration thrombectomy
Number of subjects: 2500
Study: 37949730

Group type: EXPERIMENTAL
Intervention: 32.5 Gy in five fractions
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 35 Gy in five fractions
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 37.5 Gy in five fractions
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 40 Gy in five fractions
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Higher radiation dose (37.5-40 Gy)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Favorable intermediate risk
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: All doses (32.5 to 40 Gy)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Higher dose levels
Number of subjects: 136
Study: 37949923

Group type: EXPERIMENTAL
Intervention: Intracortical microstimulation (ICMS) of S1
Number of subjects: 3

Group type: COMPARATOR
Intervention: Biomimetic stimulation
Number of subjects: 3
Study: 37949931

Group type: EXPERIMENTAL
Intervention: Surgery for visual impairment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Visual impairment at diagnosis
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Visual impairment
Number of subjects: 120
Study: 37950144

Group type: EXPERIMENTAL
Intervention: Etripamil (70 mg)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 37950216

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation intervention for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational session on HFpEF complications, functional decline, and healthy lifestyle habits for 12 weeks
Number of subjects: 0
Study: 37950230

Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage
Number of subjects: 36

Group type: COMPARATOR
Intervention: Soft tissue mobilization with therapeutic exercises
Number of subjects: 36
Study: 37950243

Group type: EXPERIMENTAL
Intervention: Partnering for Change (P4C) intervention classes
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control classes
Number of subjects: 400
Study: 37950301

Group type: EXPERIMENTAL
Intervention: Dietary counselling and omega-3 supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 50
Study: 37950338

Group type: EXPERIMENTAL
Intervention: Amcenestrant 400 mg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Amcenestrant 200 mg
Number of subjects: 95

Group type: COMPARATOR
Intervention: Letrozole 2.5 mg
Number of subjects: 95
Study: 37950370

Group type: EXPERIMENTAL
Intervention: Cerebrolysin therapy
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Olfactory and gustatory trainings
Number of subjects: 250
Study: 37950390

Group type: EXPERIMENTAL
Intervention: Ganaxolone
Number of subjects: 101
Study: 37950392

Group type: EXPERIMENTAL
Intervention: Asundexian (10/20/50 mg daily)
Number of subjects: 1746

Group type: COMPARATOR
Intervention: Placebo plus standard antiplatelet treatment
Number of subjects: 1746

Group type: EXPERIMENTAL
Intervention: Asundexian
Number of subjects: 1746
Study: 37950393

Group type: EXPERIMENTAL
Intervention: Structured active play intervention
Number of subjects: 15
Study: 37950400

Group type: EXPERIMENTAL
Intervention: Telecare consultation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual in-person clinic consultation
Number of subjects: 0
Study: 37950428

Group type: EXPERIMENTAL
Intervention: Scalpel-bougie tracheotomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rapid-sequence tracheotomy
Number of subjects: 30
Study: 37950533

Group type: EXPERIMENTAL
Intervention: 8-type HPV genotype restriction
Number of subjects: 2969

Group type: COMPARATOR
Intervention: Visual inspection with acetic acid (VIA)
Number of subjects: 2969

Group type: COMPARATOR
Intervention: Colposcopy
Number of subjects: 2969

Group type: EXPERIMENTAL
Intervention: Combination of 8-type HPV genotype restriction and VIA
Number of subjects: 2969
Study: 37950612

Group type: EXPERIMENTAL
Intervention: mHealth intervention with nutrition education and self-regulation skills curriculum
Number of subjects: 62

Group type: COMPARATOR
Intervention: Location-triggered app messaging
Number of subjects: 62

Group type: COMPARATOR
Intervention: Reflections on benefits of change with extra coaching time and tailored app messages
Number of subjects: 62

Group type: COMPARATOR
Intervention: Coach monitoring of food purchases
Number of subjects: 62

Group type: COMPARATOR
Intervention: Involvement of a household member
Number of subjects: 62
Study: 37950674

Group type: EXPERIMENTAL
Intervention: Headache attributed to influenza infection
Number of subjects: 75
Study: 37950726

Group type: EXPERIMENTAL
Intervention: Etripamil nasal spray 70 mg
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 69
Study: 37950897

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/d)
Number of subjects: 628

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Aspirin avoidance
Number of subjects: 628
Study: 37950907

Group type: EXPERIMENTAL
Intervention: Self-monitoring with research physician-optimized antihypertensive titration
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual postnatal care from a primary care physician and midwife
Number of subjects: 220
Study: 37950918

Group type: EXPERIMENTAL
Intervention: High-sodium diet (approximately 2200 mg sodium added daily to usual diet)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Low-sodium diet (approximately 500 mg daily total)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: High-sodium diet
Number of subjects: 213

Group type: COMPARATOR
Intervention: Low-sodium diet
Number of subjects: 213
Study: 37950919

Group type: EXPERIMENTAL
Intervention: Self-monitoring along with physician-optimized antihypertensive titration
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual postnatal care
Number of subjects: 220
Study: 37951069

Group type: EXPERIMENTAL
Intervention: Self-management program based on acceptance and commitment therapy
Number of subjects: 156

Group type: COMPARATOR
Intervention: Health education leaflets (Control)
Number of subjects: 156
Study: 37951218

Group type: EXPERIMENTAL
Intervention: Sequential chemoradiotherapy combined with toripalimab
Number of subjects: 22
Study: 37951245

Group type: EXPERIMENTAL
Intervention: Orismilast 20 mg
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Orismilast 30 mg
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 37951292

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg plus Ezetimibe 10 mg (combination lipid-lowering therapy)
Number of subjects: 31993

Group type: COMPARATOR
Intervention: High-intensity atorvastatin monotherapy
Number of subjects: 31993
Study: 37951560

Group type: COMPARATOR
Intervention: Standard vedolizumab (300 mg every 8 weeks)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Dose-optimized vedolizumab (600 mg at week 6, then 300 mg every 4 weeks or 600 mg at week 6, then 600 mg every 4 weeks)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Standard vedolizumab
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Dose-optimized vedolizumab
Number of subjects: 278
Study: 37951571

Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 249
Study: 37951577

Group type: EXPERIMENTAL
Intervention: Virtual reality technology (SootheVR All-In-One virtual reality care system) during extra-amniotic balloon catheter insertion
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (institutional standard care)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Virtual reality technology
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study: 37951863

Group type: EXPERIMENTAL
Intervention: Women with PAS disorders and postpartum haemorrhage (PPH), n = 879
Number of subjects: 2029

Group type: COMPARATOR
Intervention: Women with PAS disorders and normal blood loss, n = 1150
Number of subjects: 2029

Group type: EXPERIMENTAL
Intervention: Risk factors for PPH in women with PAS disorders
Number of subjects: 2029
Study: 37951881

Group type: EXPERIMENTAL
Intervention: Prothrombin time (PT)
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Activated partial thromboplastin time (APTT)
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Fibrinogen (FIB)
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: White blood cell (WBC) count
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Red blood cell (RBC) count
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Platelet count
Number of subjects: 879
Study: 37951900

Group type: EXPERIMENTAL
Intervention: End-on approach using multi-tined cannulae
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional parallel technique using straight cannulae
Number of subjects: 72
Study: 37951903

Group type: EXPERIMENTAL
Intervention: Interdisciplinary intervention (half-day consultation based on a biopsychosocial model)
Number of subjects: 47
Study: 37951954

Group type: EXPERIMENTAL
Intervention: Dostarlimab (500 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pembrolizumab (200 mg)
Number of subjects: 0
Study: 37951974

Group type: EXPERIMENTAL
Intervention: Apalutamide plus ADT
Number of subjects: 1859

Group type: COMPARATOR
Intervention: Placebo plus ADT
Number of subjects: 1859
Study: 37952030

Group type: EXPERIMENTAL
Intervention: Intracardiac delivery of autologous CD34 cells
Number of subjects: 0
Study: 37952085

Group type: EXPERIMENTAL
Intervention: Combination HSCT + IV AAVrh10 at a dose of 4E13 gc/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination HSCT + IV AAVrh10 at a dose of 2E14 gc/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: IV AAVrh10 alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: HSCT alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IV AAVrh10 alone or in addition to HSCT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy at the highest dose
Number of subjects: 0
Study: 37952114

Group type: EXPERIMENTAL
Intervention: NX-13 250 mg immediate release (IR)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: NX-13 500 mg immediate release (IR)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: NX-13 500 mg delayed release (DR)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: NX-13 (all doses)
Number of subjects: 38
Study: 37952131

Group type: EXPERIMENTAL
Intervention: Semaglutide (2.4 mg, once-weekly subcutaneous)
Number of subjects: 17604

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17604

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 17604
Study: 37952132

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily (2.5 mg twice daily when indicated)
Number of subjects: 4012

Group type: COMPARATOR
Intervention: Aspirin 81 mg daily
Number of subjects: 4012
Study: 37952133

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (hemoglobin cutoff for transfusion, 7 or 8 g per deciliter)
Number of subjects: 3504

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (hemoglobin cutoff, <10 g per deciliter)
Number of subjects: 3504
Study: 37952170

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 11
Study: 37952176

Group type: EXPERIMENTAL
Intervention: Dapagliflozin, 10 mg per day
Number of subjects: 5788

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5788

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 5788
Study: 37952180

Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg once weekly
Number of subjects: 529
Study: 37952231

Group type: EXPERIMENTAL
Intervention: Fatigued group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non-fatigued group
Number of subjects: 18
Study: 37952254

Group type: EXPERIMENTAL
Intervention: lepodisiran 4 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: lepodisiran 12 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: lepodisiran 32 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: lepodisiran 96 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: lepodisiran 304 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: lepodisiran 608 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study: 37952338

Group type: EXPERIMENTAL
Intervention: Chronic Low Back Pain (CLBP) group
Number of subjects: 202

Group type: COMPARATOR
Intervention: Achilles Tendinopathy (AT) group
Number of subjects: 202
Study: 37952548

Group type: EXPERIMENTAL
Intervention: Discontinuous oxytocin (infusion stopped beyond 6 cm dilation)
Number of subjects: 2170

Group type: COMPARATOR
Intervention: Continuous oxytocin (administration continued until delivery)
Number of subjects: 2170
Study: 37952550

Group type: EXPERIMENTAL
Intervention: Long-acting injectable cabotegravir
Number of subjects: 3290

Group type: COMPARATOR
Intervention: Daily oral tenofovir disoproxil fumarate plus emtricitabine
Number of subjects: 3290
Study: 37952714

Group type: EXPERIMENTAL
Intervention: Stepped care intervention
Number of subjects: 424

Group type: COMPARATOR
Intervention: College required mental health screening and referral
Number of subjects: 424
Study: 37952772

Group type: EXPERIMENTAL
Intervention: Citalopram or escitalopram
Number of subjects: 255
Study: 37952928

Group type: EXPERIMENTAL
Intervention: High-dose vitamin A supplementation
Number of subjects: 504

Group type: COMPARATOR
Intervention: Intermittent iron supplementation
Number of subjects: 504
Study: 37952982

Group type: EXPERIMENTAL
Intervention: Oral azacitidine (Oral-AZA) maintenance
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Injectable hypomethylating agents as first subsequent therapy (FST) after Oral-AZA
Number of subjects: 238

Group type: COMPARATOR
Intervention: Injectable hypomethylating agents as first subsequent therapy (FST) after placebo
Number of subjects: 238
Study: 37953075

Group type: EXPERIMENTAL
Intervention: Edaravone oral suspension (105 mg in 5 mL aqueous suspension) administered orally
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Edaravone oral suspension (105 mg in 5 mL aqueous suspension) administered via PEG tube
Number of subjects: 15
Study: 37953500

Group type: EXPERIMENTAL
Intervention: Linerixibat 40 mg b.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37953503

Group type: EXPERIMENTAL
Intervention: Next generation sequencing techniques including a POI-associated gene panel, extended whole exome sequencing data, and specific autoantibody assays.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard recommended diagnostic investigations including screening for chromosomal anomalies and FMR1 premutations.
Number of subjects: 100
Study: 37953814

Group type: EXPERIMENTAL
Intervention: Duvelisib (25 mg) for up to 10 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Duvelisib
Number of subjects: 28
Study: 37954037

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus platinum-based chemotherapy (arm A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus platinum-based chemotherapy (arm C)
Number of subjects: 0
Study: 37954068

Group type: EXPERIMENTAL
Intervention: H3L6 diet (high omega-3, low omega-6 diet)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: H3 diet (high omega-3, average omega-6 diet)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control diet (average intakes of omega-3 and omega-6 fatty acids)
Number of subjects: 182
Study: 37954548

Group type: EXPERIMENTAL
Intervention: Low-volume HIIT (2 × 4-min high-intensity treadmill exercise at 85%-90% of peak heart rate, 3-min active recovery)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: High-volume HIIT (4 × 4-min high-intensity treadmill exercise at 85%-90% of peak heart rate, three 3-min active recovery)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 72
Study: 37954892

Group type: EXPERIMENTAL
Intervention: Preoperative TMT-B scores
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: TMT-B as a stand-alone test
Number of subjects: 841
Study: 37954898

Group type: EXPERIMENTAL
Intervention: Genetic and clinical epidemiology of PCSK9 inhibition
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: PCSK9 inhibition
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Preventive, pretreatment settings of PCSK9 inhibition
Number of subjects: 9
Study: 37954906

Group type: EXPERIMENTAL
Intervention: Pegmolesatide (administered once every four weeks)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Epoetin alfa (administered one to three times per week)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Pegmolesatide
Number of subjects: 372

Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 372
Study: 37954964

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus etoposide and platinum (EP)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo plus etoposide and platinum (EP)
Number of subjects: 439
Study: 37955005

Group type: EXPERIMENTAL
Intervention: Once-weekly somatrogon
Number of subjects: 24

Group type: COMPARATOR
Intervention: Once-daily rhGH
Number of subjects: 24
Study: 37955353

Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy (PCNL)
Number of subjects: 4571

Group type: COMPARATOR
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 4571
Study: 37955439

Group type: EXPERIMENTAL
Intervention: Management protocol based on ICP monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Management protocol based on imaging and clinical examination without ICP monitoring
Number of subjects: 0
Study: 37955445

Group type: EXPERIMENTAL
Intervention: Wearable measure of physical activity monitoring using Apple Watch
Number of subjects: 65
Study: 37955580

Group type: EXPERIMENTAL
Intervention: In utero enzyme replacement therapy (IUERT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postnatal enzyme replacement therapy (ERT)
Number of subjects: 0
Study: 37955615

Group type: EXPERIMENTAL
Intervention: Lifestyle walking intervention combining self-monitoring and regular telephone counseling
Number of subjects: 202

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 202
Study: 37955644

Group type: EXPERIMENTAL
Intervention: Intensive Insulin Management
Number of subjects: 0